These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 6502472)
21. Disopyramide pharmacokinetics in patients with acute myocardial infarction. Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785 [TBL] [Abstract][Full Text] [Related]
22. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Bryson SM; Whiting B; Lawrence JR Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284 [TBL] [Abstract][Full Text] [Related]
23. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. Upton RA; Williams RL J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738 [TBL] [Abstract][Full Text] [Related]
24. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Cunningham JL; Shen DD; Shudo I; Azarnoff DL Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. Johnston A; Henry JA; Warrington SJ; Hamer NA Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241 [TBL] [Abstract][Full Text] [Related]
26. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model. Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog. Karim A; Kook C; Novotney RL; Zagarella J; Campion J Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556 [TBL] [Abstract][Full Text] [Related]
28. Stereoselective disposition and metabolism of disopyramide in pediatric patients. Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088 [TBL] [Abstract][Full Text] [Related]
29. Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers. Bonde J; Jensen NM; Pedersen LE; Graudal NA; Angelo HR; Kampmann JP Pharmacol Toxicol; 1988 May; 62(5):298-301. PubMed ID: 3413032 [TBL] [Abstract][Full Text] [Related]
30. Disposition kinetics of disopyramide in patients with renal insufficiency. Shen DD; Cunningham JL; Shudo I; Azarnoff DL Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of disopyramide in patients with chronic renal failure. Francois B; Mallein R; Rondelet J; Lussignol M Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798 [TBL] [Abstract][Full Text] [Related]
32. Disopyramide kinetics in renal impairment: determinants of interindividual variability. Burk M; Peters U Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909 [TBL] [Abstract][Full Text] [Related]
37. The stereoselective disposition of disopyramide in the dog. Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331 [TBL] [Abstract][Full Text] [Related]
38. In vivo interaction of the enantiomers of disopyramide in human subjects. Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736 [TBL] [Abstract][Full Text] [Related]